Nanotechnology

Nanotechnology, a child sector within Superscout's Frontier & Deep Tech category, encompasses the manipulation of matter at the nanoscale (1-100 nanometers) to create materials, devices, and systems with novel properties for applications in electronics, medicine, energy, and manufacturing. With 14 funders actively investing in nanotechnology startups tracked in Superscout's database, the sector draws capital from deep tech venture funds, life science crossover investors, and government-linked investment vehicles that view nanoscale innovation as foundational to next-generation technology platforms.

The nanotechnology investment thesis spans multiple application domains where nanoscale engineering creates step-function improvements in performance. In medicine, nanoparticle drug delivery systems enable targeted therapeutics that reduce side effects while increasing efficacy, with mRNA vaccines (which use lipid nanoparticles) demonstrating the category's potential at massive scale. In electronics, nanoscale fabrication is fundamental to semiconductor advancement beyond current lithographic limits. In energy, nanomaterials are improving solar cell efficiency, battery performance, and catalytic processes. In materials science, nanocoatings, nanocomposites, and nanofibers are creating materials with superior strength, conductivity, or barrier properties.

Superscout's stage data shows 12 funders (86%) at seed, 6 (43%) at pre-seed, 5 (36%) at Series A, 2 (14%) at Series B, and 1 (7%) at growth equity. The median minimum check is $500,000, median maximum is $7 million, and the 75th percentile reaches $7.25 million. The high seed concentration with steep drop-off at later stages reflects the science-heavy nature of nanotechnology startups that often emerge from university labs: many attract early funding for research but face the "valley of death" between laboratory demonstration and commercial manufacturing at scale.

For nanotechnology founders, the 2025-2026 funding environment rewards companies that have identified specific, near-term commercial applications for their nanoscale innovations rather than pursuing general-purpose platform approaches, and that have de-risked manufacturing scale-up through partnerships with established manufacturers or through pilot production facilities.